Biochemical outcome for hormone-naive patients with Gleason score 3+4 versus 4+3 prostate cancer undergoing permanent prostate brachytherapy

Urology

Volumn 60, Issue 1, 2002, Pages 98-103

  Merrick, Gregory S ^a,b   Butler, Wayne M ^a   Galbreath, Robert W ^a,c   Lief, Jonathan H ^a,c   Adamovich, Edward ^d  

^a WHEELING HOSPITAL   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c WHEELING JESUIT UNIVERSITY   (United States)

^d WHEELING HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE; IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; BIOPSY; BLOOD LEVEL; BRACHYTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMICAL PARAMETERS; CLINICAL FEATURE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG IMPLANTATION; ECHOGRAPHY; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; ORGANIZATION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SCORING SYSTEM; SEMINAL VESICLE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PALLADIUM; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOTHERAPY, CONFORMAL; TREATMENT OUTCOME;

EID: 0036294273     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01640-0     Document Type: Article

References (24)

1. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update
2. Should Gleason score 7 prostate cancer be considered a unique grade category?
3. Palladium-103 brachytherapy for prostate carcinoma
4. Modern prostate brachytherapy: Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up
5. Simultaneous irradiation for prostate cancer: Intermediate results with modern techniques
6. Five-year biochemical outcome following permanent interstitial brachytherapy for T1-T3 prostate cancer
7. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy
8. Gleason score 7 prostate cancer: A heterogenous entity? Correlation with pathologic parameters and disease-free survival
9. A neural network predicts progression for men with Gleason score 3+4 versus 4+3 tumors after radical prostatectomy
10. Outcome and predictive factors for patients with Gleason score 7 prostate carcinoma treated with three-dimensional conformal external beam radiation therapy
11. Consensus statement: Guidelines for PSA following radiation therapy
12. The impact of Gleason score accuracy as a criterion for prostate brachytherapy patient selection
13. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43
14. Comparison of seed loading approaches in prostate brachytherapy
15. Modified uniform seed loading for prostate brachytherapy: Rationale, design, and evaluation
16. Potential role of various dosimetric quality indicators in prostate brachytherapy
17. The effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation
18. Seed fixity in the prostate/periprostatic region following brachytherapy
19. Extracapsular radiation dose distribution following permanent prostate brachytherapy
20. Molecular determination of surgical margins using fossa biopsies at radical prostatectomy
21. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings
22. Isotope selection for patients undergoing prostate brachytherapy
23. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy